Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 605-399-0 | CAS number: 165252-70-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Dermal absorption
Administrative data
- Endpoint:
- dermal absorption in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20/09/2005 - 05/04/2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP, Guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 006
- Report date:
- 2006
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.7600 (Dermal Penetration)
- Version / remarks:
- (1998)
- Deviations:
- no
- GLP compliance:
- yes
Test material
- Reference substance name:
- (RS)-1-methyl-2-nitro-3-(tetrahydro-3-furylmethyl)guanidine
- EC Number:
- 605-399-0
- Cas Number:
- 165252-70-0
- Molecular formula:
- C7H14N4O3
- IUPAC Name:
- (RS)-1-methyl-2-nitro-3-(tetrahydro-3-furylmethyl)guanidine
- Test material form:
- other: soild
- Details on test material:
- Purity non-labelled test item: 97.26%
Purity labelled test item: Radiochemical purity after purification 98.5% by HPLC
Batch No. non-labelled test item: 5500310
Batch No. labelled test item: CP-2499
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- [14C- guanidine]dinotefuran ([G-14C])
Test animals
- Species:
- rat
- Strain:
- other: Sprague Dawley, SPF quality (outbred)
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Source: RCC Ltd, Laboratory Animal Services, Füllinsdorf, Switzerland
Age: 8 – 9weeks at acclimatization
Body weight: approximately 260 g
Administration / exposure
- Type of coverage:
- open
- Vehicle:
- water
- Remarks:
- MilliQ
- Duration of exposure:
- Exposre period: 24 hours, with interim kills of 4 rats per group after 0.5, 1, 2, 4 and 10 hours exposure.
- Doses:
- Concentration of test substance: 3.2, 30 and 302 µg/cm2
Specific gravity: 156 µCi/mg (5760 kBq/mg) - No. of animals per group:
- 24 males/6 subgroups/group
- Control animals:
- no
- Details on study design:
- Preparation of test site: Clipped and wiped with acetone under anaesthesia with isofluorane. O-ring (inside area of approximately 25 - 35 cm2) was used.
Volume applied: 100µL of application solution was applied to the skin inside the O-ring using a syringe and spread evenly.
Size of test site: 10 cm²
Sampling time: 0.5, 1, 2, 4, 10 and 24 hours after initiation of skin contact
Housing and feeding condition: animals were housed individually throughout the experiment and fed certified standard diet ad libitum. - Details on in vitro test system (if applicable):
- Not applicable
Results and discussion
- Signs and symptoms of toxicity:
- no effects
- Remarks:
- The slight weight loss of animals was attributed to the stress and discomfort during the experiment. At dissection urinary calculi were found in the urinary bladder with cloudy urine of one animal of group 3.
- Dermal irritation:
- no effects
- Remarks:
- There was no evidence of skin irritation.
- Absorption in different matrices:
- Percutaneous absorption:
Low dose group (see Table 2):
After dermal application, systemic absorption was increased with the exposure time from 0.5 hours to 10 hours, but thereafter it remained almost constant. Therefore systemic absorption during a 24-hour exposure was calculated to be 0.81% of the applied dose. The concentration of radioactivity (RA) in blood was below the limit of quantification (LOQ) at all sampling time points. A major part of the applied RA was found in the skin wash which decreased with exposure time from 85% of dose after 0.5 hours to 60% of dose after 10 hours but no further change was observed between 10 hours and 24 hours. Correspondingly, the RA in the stratum corneum (tape strips) increased from 7.4% after 0.5 hours to 35% of the applied dose after 10 hours of exposure. The lower skin layers, corium and subcutis, showed very low amounts of RA (less than 1%) and 0.3-4.8% of the dose was recovered in the cover and O-ring. The systemically absorbed test item was rapidly excreted with the urine and only 0.11 % of the dose remained in the animals 24 hours after the start of exposure. The mean penetration rate for the 24-hour exposure time was calculated to be 0.0011 µg/cm2/hour.
Middle dose group (See Table 3):
After dermal application, absorption was only 0.48% during an exposure of 24 hours. The highest values were found 1 and 4 hours after start of exposure accounting for 1.43% and 1.15% of the applied dose, respectively, but a high inter-individual variation was observed. The concentrations of RA in blood were below the limit of quantification (LOQ) at most of the sampling time points, and 0.0033 and 0.0134 ppm dinotefuran equivalents were determined after 0.5 and 1 hour, respectively. A major part of the applied RA was recovered in the skin wash which was decreased with exposure time from 90% of dose after 0.5 hours to 69% of dose after 10 hours but no further change was observed between 10 hours and 24 hours. Correspondingly, the RA in the stratum corneum increased with exposure time and reached 26% of the applied dose after an exposure period of 24 hours. The lower skin layers, corium and subcutis, showed very low amounts of RA (less than 0.5%) and in the range 0.05-3.2% of the dose were recovered in the cover and O-ring. The systemically absorbed test item was rapidly excreted with the urine and only 0.09 % of the dose remained in the animals 24 hours after the start of exposure. The mean penetration rate for the 24 hours exposure time was calculated to be 0.0060 µg/cm2/hour.
High dose group (see Table 4):
After dermal application, absorption was 1.04% during an exposure of 24 hours. Higher values of dermal absorption were found at 1, 4 and 10 hours after start of exposure accounting for 1.41%, 2.10% and 1.44% of the applied dose, respectively, but a high inter-individual variation was observed. The highest concentration in blood was found 1 hour after the start of exposure accounting for 0.1773 ppm dinotefuran equivalents. Thereafter the concentrations decreased rapidly to values close to the limit of quantification. A large amount of RA was found in the skin wash. It decreased only slightly with ongoing exposure time, i.e. 93% of the dose after 0.5 hours to 86% of the dose after 10 hours. After 1 hour of exposure 8% of the applied dose had penetrated into the stratum corneum. This level was almost constant until 24 hours. The lower skin layers, corium and subcutis, showed very low amounts of RA. The systemically absorbed test item was rapidly excreted with the urine and only 0.09 % of the dose was still remaining in the animals 24 hours after start of exposure. The mean penetration rate for the 24 hours exposure time was calculated to be 0.1309 µg/cm2/hour.
Analysis of skin wash:
See Table 5
The skin wash samples of the individual animals were pooled for every sampling time point and dose level, and analyzed by HPLC. In all analyses more than 96% of the RA was found as unchanged dinotefuran. Therefore it was concluded that the applied test substance remained stable at the application site over the whole exposure period. - Total recovery:
- See Table 1
Mean total recoveries of radioactivity were high (95.4-99.1%) in all dose groups at all time points and the systemically absorbed dose was rapidly excreted, predominantly in urine.
Percutaneous absorptionopen allclose all
- Dose:
- 3.2 µg/cm²
- Parameter:
- percentage
- Absorption:
- 97.2 %
- Remarks on result:
- other: 0.5 h
- Dose:
- 3.2 µg/cm²
- Parameter:
- percentage
- Absorption:
- 99.1 %
- Remarks on result:
- other: 4 h
- Dose:
- 3.2 µg/cm²
- Parameter:
- percentage
- Absorption:
- 96.9 %
- Remarks on result:
- other: 24 h
- Dose:
- 30 µg/cm²
- Parameter:
- percentage
- Absorption:
- 96.6 %
- Remarks on result:
- other: 0.5 h
- Dose:
- 30 µg/cm²
- Parameter:
- percentage
- Absorption:
- 97.7 %
- Remarks on result:
- other: 4 h
- Dose:
- 30 µg/cm²
- Parameter:
- percentage
- Absorption:
- 97.7 %
- Remarks on result:
- other: 24 h
- Dose:
- 302 µg/cm²
- Parameter:
- percentage
- Absorption:
- 97 %
- Remarks on result:
- other: 0.5 h
- Dose:
- 302 µg/cm²
- Parameter:
- percentage
- Absorption:
- 95.4 %
- Remarks on result:
- other: 4 h
- Dose:
- 302 µg/cm²
- Parameter:
- percentage
- Absorption:
- 96.3 %
- Remarks on result:
- other: 24 h
Any other information on results incl. tables
Table 1: Summary of mean mass balance and systemic absorption
Dose level (µg/cm2) |
Matrix |
Radioactivity in%of applied dose: |
|||||
0-0.5 h |
0-1 h |
0-2 h |
0-4 h |
0-10 h |
0-24 h |
||
3.2 |
Systemic absorption |
0.2 |
0.2 |
0.4 |
0.7 |
1.2 |
0.8 |
Dislodged dose |
89.5 |
78.7 |
67.4 |
68.9 |
61.5 |
60.7 |
|
Stratum corneum (outer skin) |
7.4 |
18.1 |
31.0 |
29.2 |
34.8 |
34.6 |
|
Corium+subcutis (inner skin) |
0.1 |
0.2 |
0.3 |
0.5 |
0.6 |
0.8 |
|
Total |
97.2 |
97.2 |
99.1 |
99.1 |
97.9 |
96.9 |
|
30 |
Systemic absorption |
0.3 |
1.4 |
0.3 |
1.2 |
0.8 |
0.5 |
Dislodged dose |
90.5 |
83.8 |
74.5 |
77.6 |
71.9 |
71.2 |
|
Stratum corneum (outer skin) |
5.6 |
12.5 |
21.9 |
18.8 |
24.7 |
25.6 |
|
Corium+subcutis (inner skin) |
0.2 |
0.5 |
0.2 |
0.1 |
0.2 |
0.4 |
|
Total |
96.6 |
98.3 |
96.9 |
97.7 |
97.6 |
97.7 |
|
302 |
Systemic absorption |
0.2 |
1.4 |
0.9 |
2.1 |
1.4 |
1.0 |
Dislodged dose |
93.3 |
85.8 |
88.9 |
86.7 |
86.1 |
86.1 |
|
Stratum corneum (outer skin) |
3.4 |
8.0 |
7.8 |
6.4 |
7.8 |
9.0 |
|
Corium+subcutis (inner skin) |
0.1 |
0.5 |
0.1 |
0.2 |
0.1 |
0.2 |
|
Total |
97.0 |
95.7 |
97.7 |
95.4 |
95.4 |
96.3 |
Table 2:Balance of radioactivity and excretion pattern – low dose group (3.2µg/cm2)
Matrix |
Radioactivity in%of applied dose: |
|||||||||||
0-0.5 hours |
0-1 hours |
0-2 hours |
0-4 hours |
0-10 hours |
0-24 hours |
|||||||
Mean |
SD |
Mean |
SD |
Mean |
SD |
Mean |
SD |
Mean |
SD |
Mean |
SD |
|
Urine |
<0.01 |
<0.01 |
0.02 |
0.01 |
0.14 |
0.16 |
0.45 |
0.49 |
0.97 |
0.50 |
0.62 |
0.48 |
Faeces |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
0.02 |
<0.01 |
Cage wash |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
0.01 |
0.03 |
0.01 |
0.02 |
0.01 |
0.05 |
0.07 |
TOTAL EXCRETION |
0.01 |
<0.01 |
0.03 |
0.02 |
0.16 |
0.18 |
0.48 |
0.49 |
1.00 |
0.51 |
0.69 |
0.53 |
Blood |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
Untreated skin |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
GI tract + contents |
0.02 |
<0.01 |
0.02 |
<0.01 |
0.03 |
<0.01 |
0.03 |
0.01 |
0.03 |
<0.01 |
0.02 |
<0.01 |
Carcass |
0.13 |
0.01 |
0.15 |
0.02 |
0.16 |
0.03 |
0.14 |
0.05 |
0.12 |
0.02 |
0.09 |
0.02 |
Sub-total |
0.16 |
0.02 |
0.18 |
0.03 |
0.19 |
0.04 |
0.18 |
0.06 |
0.15 |
0.02 |
0.11 |
0.02 |
SYSTEMICABSORPTION |
0.17 |
0.02 |
0.20 |
0.03 |
0.35 |
0.21 |
0.65 |
0.55 |
1.15 |
0.52 |
0.81 |
0.52 |
TapeStrips (stratum corneum) |
7.42 |
0.31 |
18.06 |
6.04 |
30.97 |
4.40 |
29.15 |
2.88 |
34.77 |
5.40 |
34.63 |
1.08 |
Remaining treated skin |
0.09 |
0.03 |
0.17 |
0.03 |
0.31 |
0.10 |
0.45 |
0.37 |
0.56 |
0.25 |
0.77 |
0.47 |
APPRICATION SITE |
7.51 |
0.33 |
18.24 |
6.07 |
31.27 |
4.37 |
29.60 |
3.20 |
35.33 |
5.28 |
35.40 |
1.55 |
Skin wash |
84.70 |
6.55 |
78.04 |
3.04 |
66.83 |
3.72 |
68.60 |
4.11 |
59.78 |
6.09 |
59.10 |
5.46 |
O-ring/covers |
4.79 |
6.08 |
0.67 |
1.07 |
0.60 |
0.76 |
0.30 |
0.30 |
1.68 |
3.04 |
1.62 |
2.70 |
DISLODGEDDOSE |
89.49 |
0.68 |
78.71 |
2.70 |
67.43 |
3.40 |
68.90 |
3.98 |
61.46 |
5.43 |
60.72 |
2.99 |
TOTALRECOVERY |
97.18 |
0.56 |
97.15 |
3.38 |
99.05 |
0.98 |
99.14 |
0.80 |
97.93 |
0.58 |
96.93 |
1.63 |
Table 3:Balance of radioactivity and excretion pattern – middle dose group(30 µg/cm2)
Matrix |
Radioactivity in%of applied dose: |
|||||||||||
0-0.5 hours |
0-1 hours |
0-2 hours |
0-4 hours |
0-10 hours |
0-24 hours |
|||||||
Mean |
SD |
Mean |
SD |
Mean |
SD |
Mean |
SD |
Mean |
SD |
Mean |
SD |
|
Urine |
0.04 |
0.04 |
0.40 |
0.42 |
0.12 |
0.02 |
0.88 |
0.88 |
0.65 |
0.66 |
0.36 |
0.26 |
Faeces |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
0.01 |
<0.01 |
Cage wash |
<0.01 |
<0.01 |
0.03 |
0.05 |
<0.01 |
<0.01 |
0.05 |
0.05 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
TOTAL EXCRETION |
0.04 |
0.04 |
0.43 |
0.46 |
0.13 |
0.02 |
0.93 |
0.93 |
0.67 |
0.67 |
0.38 |
0.27 |
Whole blood |
<0.01 |
<0.01 |
0.03 |
0.02 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
Untreated skin |
<0.01 |
<0.01 |
0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
<0.01 |
GI tract + contents |
0.02 |
0.01 |
0.09 |
0.09 |
0.02 |
<0.01 |
0.03 |
0.02 |
0.02 |
<0.01 |
0.01 |
<0.01 |
Carcass |
0.20 |
0.10 |
0.87 |
0.57 |
0.14 |
0.01 |
0.17 |
0.04 |
0.10 |
<0.01 |
0.08 |
<0.01 |
Sub-total |
0.24 |
0.12 |
1.00 |
0.67 |
0.17 |
0.02 |
0.21 |
0.06 |
0.12 |
0.01 |
0.09 |
<0.01 |
SYSTEMICABSORPTION |
0.28 |
0.16 |
1.43 |
1.13 |
0.30 |
0.03 |
1.15 |
0.98 |
0.78 |
0.68 |
0.48 |
0.27 |
TapeStrips (stratum corneum) |
5.59 |
1.62 |
12.51 |
4.33 |
21.87 |
1.35 |
18.75 |
3.43 |
24.73 |
5.40 |
25.62 |
3.34 |
Remaining treated skin |
0.15 |
0.12 |
0.49 |
0.44 |
0.20 |
0.07 |
0.14 |
0.03 |
0.16 |
0.05 |
0.40 |
0.22 |
APPRICATION SITE |
5.74 |
1.70 |
13.00 |
4.63 |
22.06 |
1.39 |
18.89 |
3.43 |
24.89 |
5.35 |
26.02 |
3.31 |
Skin wash |
90.49 |
3.23 |
83.62 |
5.58 |
71.30 |
1.75 |
74.44 |
4.48 |
69.12 |
3.75 |
70.07 |
4.67 |
O-ring/covers |
0.05 |
0.02 |
0.22 |
0.27 |
3.22 |
2.70 |
3.17 |
6.11 |
2.82 |
2.81 |
1.12 |
1.95 |
DISLODGEDDOSE |
90.54 |
3.23 |
83.84 |
5.69 |
74.51 |
1.02 |
77.61 |
2.90 |
71.94 |
5.58 |
71.19 |
3.72 |
TOTALRECOVERY |
96.55 |
3.37 |
98.27 |
0.96 |
96.88 |
0.83 |
97.65 |
1.34 |
97.62 |
1.22 |
97.69 |
1.04 |
Applicant's summary and conclusion
- Conclusions:
- A large proportion of the dermally applied dinotefuran (60.7 – 93.3%) remained on the surface of the skin and could be dislodged by washing, and was not available for absorption into the skin or systemic circulation. Therefore, systemic absorption of dinotefuran was very low at all time points for all dose levels.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)